Nano cap Seelos Therapeutics (SEEL +7%) is up out of the gate this morning in reaction to its update on SLS-007, its second gene therapy candidate for the potential treatment of Parkinson’s disease.
An in vivo study delivering SLS-007, a
family of peptidic inhibitors designed to block the aggregation of
α-synuclein in the brain, via an adeno-associated virus (AAV) is set to
begin. Data to determine delivery and target engagement should be
available in H2.
The company’s other PD candidate, SLS-004, is an
all-in-one lentiviral gene therapy that targets the gene that encodes
for the production of α-synuclein.
https://seekingalpha.com/news/3535150-seelos-up-7-on-advancement-of-second-gene-therapy-for-parkinsons
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.